The probability of relapse and disability progression during pregnancy was associated with time when natalizumab was stopped and number of relapses in the year before natalizumab treatment. from Front page feed https://ift.tt/3eJiJM2
Biohaven Pharmaceutical’s oral acute migraine agent rimegepant (Nurtec ODT) is the first branded medication available through Cove’s platform, which provides consults with independent health care providers and access to prescriptions. from Front page feed https://ift.tt/2xQmf6z
Results from one of the first multi-case studies of neurologic manifestations of COVID-19 demonstrate complex CNS involvement and raise further questions about pathological mechanism. from Front page feed https://ift.tt/3brgtHd
The first presumptive case of acute necrotizing encephalopathy in a patient with confirmed COVID-19 has been published in the journal Radiology. from Front page feed https://ift.tt/3c9OmMy
The phase 3 study will commence following the results of the phase 2b/3 AB10015 study, in which masitinib significantly slowed disease progression in combination with riluzole. from Front page feed https://ift.tt/2VrxbiO
The FDA has moved the PDUFA date for risdiplam back to August 24, 2020, as the agency works to review additional data that was made available from part 2 of the pivotal SUNFISH trial. from Front page feed https://ift.tt/2z38q57
New data suggest that brain changes in the posterior cingulate cortex and precuneus as a result of SDB may increase the risk of Alzheimer disease, supporting prior findings which imply a link between the conditions. from Front page feed https://ift.tt/39So9Ax
Researchers noted at least a 50% reduction from baseline in mean number of moderate to severe migraine days per month in 48% of the rimegepant group. from Front page feed https://ift.tt/2xZpJ6d
The agency has assigned a PDUFA date of July 31, 2020, for the purified CBD treatment which has been previously approved for Dravet and Lennox-Gastaut syndromes. from Front page feed https://ift.tt/2XhxAHd
Nearly all patients in this cohort achieved a clinically meaningful >3-point increase during the study period, demonstrating a consistent response to the gene therapy. from Front page feed https://ift.tt/2WWn6gj
Catabasis’s small molecule NF-kB inhibitor showed promise in phase 2, and the phase 3 PolarisDMD study (NCT03703882) of edasalonexant is fully enrolled and expected to read out in late 2020. from Front page feed https://ift.tt/3anrvMV
Although the drug requires no CYP2C9 genotyping or first-dose observation, an up-titration scheme should be used due to the risk of transient cardiac conduction issues. from Front page feed https://ift.tt/3amkLPl
SK Life Science’s newly approved treatment for partial-onset seizures is set to launch in the second quarter of 2020, after being designated Schedule V by the DEA. from Front page feed https://ift.tt/3d0ehHI
The report suggests with moderate certainty that all 3 therapies offer a small or substantial net health benefit and with a high certainty of at least a small net health benefit. from Front page feed https://ift.tt/2vvEk8U
Disease-modifying therapies used to treat several immune-mediated disorders in neurology may make patients more susceptible to the novel coronavirus. from Front page feed https://ift.tt/3910Zrq
The drug was previously approved for the treatment of acute repetitive seizures and granted 7 years of orphan drug exclusivity in January 2020. from Front page feed https://ift.tt/2wKz55k
The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020. from Front page feed https://ift.tt/3aKone0
Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose. from Front page feed https://ift.tt/335u6Zf
The VMAT2 inhibitor failed to meet the primary end point in the ARTISTS 1 and ARTISTS 2 trials in the treatment of tics in pediatric patients with Tourette syndrome. from Front page feed https://ift.tt/2PMnlGm